Want to see TOI full AI Analyst Report?
TOI Stock Chart & Stats
$3.85
-$0.01(-3.73%)
At close: 4:00 PM EST
$3.85
-$0.01(-3.73%)
Day’s Range― - ―
52-Week Range$2.32 - $6.11
Previous CloseN/A
Volume198.36K
Average Volume (3M)1.89M
Market Cap
$584.90M
Enterprise Value$599.49M
Total Cash (Recent Filing)$30.28M
Total Debt (Recent Filing)$104.86M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Aug 11, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding99,982,930
10 Day Avg. Volume2,105,444
30 Day Avg. Volume1,887,546
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)-209.23
Price to Sales (P/S)6.54
P/FCF Ratio-118.37
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.10
Enterprise Value/Gross Profit7.41
Enterprise Value/Ebitda-20.51
Forecast
1Y Price Target
$8.50Price Target Upside120.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.15
Revenue Forecast (FY)$651.94M
Bulls Say, Bears Say
Bulls Say
Capitation / Value-based Revenue MixA meaningful shift toward capitation increases predictable, per-member revenue and aligns incentives to manage total oncology costs. Growing capitated mix reduces pure volume sensitivity, supports steadier margins when utilization is managed, and underpins durable revenue visibility as delegated MA lives expand.
Specialty Pharmacy ScaleLarge and rapidly growing specialty pharmacy provides a diversified, higher-volume revenue stream with scalable unit economics. Stable pharmacy gross margin and doubling of fills indicate durable operational scale that can drive margin recovery, cash conversion and cross-sell opportunities across clinic services over the medium term.
Improving Profitability & FCF GuidanceManagement materially upgraded free cash flow guidance and has shown narrowing losses and better operating cash flow. These trends signal improving operating leverage and a path toward self-funding, reducing long-term dependence on external capital if execution on cost and capitation scale continues.
Bears Say
Negative Stockholders' EquityNegative equity reflects multi-year accumulated losses that constrain capital flexibility and increase sensitivity to adverse operational shocks. It limits ability to absorb losses, raises refinancing and covenant risk, and can force dilution or asset-backed borrowing under stress, affecting strategic optionality.
Persistent Negative Operating & Free Cash FlowSustained negative operating and free cash flow means the business still relies on external financing for growth and operations. Even with improvement, ongoing cash burn elevates refinancing and dilution risk and constrains reinvestment capacity, pressuring long-term sustainability absent continued margin gains.
Margin Pressure From Delegated ContractsRamping delegated/value-based contracts and conservative reserves have compressed patient services margins, reflecting structural trade-offs as capitation grows. If delegated economics or pricing trends continue to lag, margin dilution could persist even as revenue shifts, limiting profitability leverage from scale.
Oncology Institute News
TOI FAQ
What was Oncology Institute, Inc.’s price range in the past 12 months?
Oncology Institute, Inc. lowest stock price was $2.32 and its highest was $6.11 in the past 12 months.
What is Oncology Institute, Inc.’s market cap?
Oncology Institute, Inc.’s market cap is $584.90M.
When is Oncology Institute, Inc.’s upcoming earnings report date?
Oncology Institute, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 30 days.
How were Oncology Institute, Inc.’s earnings last quarter?
Oncology Institute, Inc. released its earnings results on May 07, 2026. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.088 by $0.068.
Is Oncology Institute, Inc. overvalued?
According to Wall Street analysts Oncology Institute, Inc.’s price is currently Undervalued.
Does Oncology Institute, Inc. pay dividends?
Oncology Institute, Inc. does not currently pay dividends.
What is Oncology Institute, Inc.’s EPS estimate?
Oncology Institute, Inc.’s EPS estimate is -0.06.
How many shares outstanding does Oncology Institute, Inc. have?
Oncology Institute, Inc. has 99,982,930 shares outstanding.
What happened to Oncology Institute, Inc.’s price movement after its last earnings report?
Oncology Institute, Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.088. Following the earnings report the stock price went down -1.72%.
Which hedge fund is a major shareholder of Oncology Institute, Inc.?
Currently, no hedge funds are holding shares in TOI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncology Institute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (120.78% Upside)
$8.50 (120.78% Upside)
Blogger Sentiment
Bullish
TOI Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 217.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $488.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 19.9%
Last 30 Days ▲ 19.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
105.22%
12-Months-Change
Fundamentals
Return on Equity
326.77%
Trailing 12-Months
Asset Growth
2.58%
Trailing 12-Months
Company Description
Oncology Institute, Inc.
The Oncology Institute (TOI) is a specialized healthcare provider delivering a full range of medical oncology services throughout the United States. Its comprehensive offerings include direct physician care, integrated on-site infusion and medication dispensing facilities, and advanced clinical trial management. The institute also provides radiation therapy, specialized outpatient programs for stem cell transplants and transfusions, and robust patient support services. Furthermore, TOI is actively involved in operating palliative care initiatives and overseeing clinical trials. These services are specifically designed to meet the needs of adult and senior cancer patients. The company maintains a significant operational footprint with 67 clinic locations. The Oncology Institute was established in 2007 and is headquartered in Cerritos, California.
TOI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: substantial revenue growth (41% YoY), exceptional specialty pharmacy scale, capitation expansion and improved operating leverage drove better adjusted EBITDA and materially upgraded free cash flow guidance. Key operational milestones include Florida market profitability, planned expansion to ~200,000 delegated MA lives, and on-track AI and portal initiatives that are expected to further drive margins and ancillary capture. Headwinds include fee-for-service revenue decline, margin pressure in patient services due to ramping delegated contracts and seasonality in Q1, a reduction in average revenue per pharmacy fill, and refinancing/liquidity considerations. Overall, positive execution and upgraded cash flow outlook outweigh the manageable near-term margin and financing risks.View all TOI earnings summariesTOI Stock 12 Month Forecast
Average Price Target
$8.50
▲(120.78% Upside)
Technical Analysis
Ownership Overview
24.06% Insiders
7.06% Mutual Funds
0.01% Other Institutional Investors
60.12% Public Companies and
Individual Investors